The 10-second takeaway
For the quarter ended March 31 (Q4), Forest Laboratories beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly. Non-GAAP earnings per share contracted significantly. GAAP earnings per share dropped significantly.
Margins contracted across the board.
Forest Laboratories logged revenue of $821.7 million. The 19 analysts polled by S&P Capital IQ hoped for revenue of $806.2 million on the same basis. GAAP reported sales were 22% lower than the prior-year quarter's $1.05 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.25. The 19 earnings estimates compiled by S&P Capital IQ forecast $0.16 per share. Non-GAAP EPS of $0.25 for Q4 were 68% lower than the prior-year quarter's $0.78 per share. GAAP EPS of $0.17 for Q4 were 76% lower than the prior-year quarter's $0.72 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 78.4%, 90 basis points worse than the prior-year quarter. Operating margin was 3.8%, much worse than the prior-year quarter. Net margin was 5.5%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $803.9 million. On the bottom line, the average EPS estimate is $0.13.
Next year's average estimate for revenue is $3.50 billion. The average EPS estimate is $1.02.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Forest Laboratories is outperform, with an average price target of $38.95.
- Add Forest Laboratories to My Watchlist.